Author Affiliations1State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130; Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
2State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130; Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
3State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130; Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
4State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130
5State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130; Institute of Regional Pathology and Pathomorphology SB RAMS 630117, Novosibirsk, Timakov str., 2
6State Novosibirsk Regional Clinical Hospital 630087, Novosibirsk, Nemirovich-Danchenko str., 130
1. Russian clinical practice guidelines for the diagnosis and treatment of lymphoproliferative diseases / Ed. I. Poddubnaya, V.G. Savchenko. Moscow: Media Medica, 2013. 104 p. (in Russian)
2. Chavynchak R.B., Rekhtina I.G. Prognostic factors in multiple myeloma complicated with renal failure // Terapevticheskiy arkhiv. 2008. 80. (1). 84–88. (in Russian)
3. Abildgaard N., Bendix-Hansen K., Kristensen J.E. et al. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum // Br. J. Haematol. 1997. 99. (3). 641–648.
4. Babarović E., Valković T., Štifter S. et al. Assessment of bone marrow fibrosis and angiogenesis in monitoring patients with multiple myeloma // Am. J. Clin. Pathol. 2012. 137. (6). 870–878.
5. Bladé J., Samson D., Reece D. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant // Br. J. Haematol. 1998. 102. (5). 1115–1123.
6. Chen H.S., Liu E.B., Wang T.T. et al. Morphologic and clinical study of 131 cases of plasma cell myeloma // Zhonghua Bing Li Xue Za Zhi. 2004. 33. (1). 44–48.
7. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival // Cancer. 1975. 36. (3). 842–854.
8. Frassanito M.A., Rao L., Moschetta M. et al. Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies // Leukemia. 2014. 28. (4). 904–916.
9. Gangat N., Wolanskyj A.P. Anemia of chronic disease // Semin. Hematol. 2013. 50. (3). 232–238.
10. Huang Y.W., Hamilton A., Arnuk O.J. et al. Current drug therapy for multiple myeloma // Drugs. 1999. 57. (4). 485–506.
11. Huang X., Pierce L.J., Chen G.L. et al. Erythropoietin receptor signaling regulates both erythropoiesis and megakaryopoiesis in vivo // Blood Cells Mol. Dis. 2010. 144. (1). 1–6.
12. Kuter D.J., Bain B., Mufti G. et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres // Br. J. Haematol. 2007. 139. (3). 351–362.
13. Kyle R.A., Rajkumar S.V. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma // Leukemia. 2009. 23. (1). 3–9.
14. Lauta V.M. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications // Cancer. 2003. 97(10). 2440–2452.
15. Petrusenko E.E., Domnikova N.P., Nepomnyashchikh G.I., Mal’tseva N.A. Changes in bone marrow and peripheral compartments of the erythron under the effect of tumor cells in indolent non-Hodgkin lymphomas and multiple myeloma // Bull. Exp. Biol. Med. 2010. 150. (3). 359–364.
16. Singhal N., Singh T., Singh Z.N. et al. Histomorphology of multiple myeloma on bone marrow biopsy // Indian J. Pathol. Microbiol. 2004. 47. (3). 359–363.
17. Subramanian R., Basu D., Dutta T.K. Significance of bone marrow fibrosis in multiple myeloma // Pathology. 2007. 39. (5). 512–515.
18. Tadmor T., Shvidel L., Aviv A. et al. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: a study of 176 patients with prognostic implications // Cancer. 2013. 119. (10). 1853–1859.
19. Thiele J., Kvasnicka H.M., Facchetti F. et al. European consensus on grading bone marrow fibrosis and assessment of cellularity // Haematologica. 2005. 90. 1128–1132.
20. Wynn T.A. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases // J. Clin. Invest. 2007. 117. (3). 524–529.
About Authors (Correspondence):
Domnikova N.P. – doctor of medical sciences, professor, head of laboratory of molecular cellular and immunomorphological basis of oncohematology, head of hematology department with aseptic wards, e-mail: n_domnikova@mail.ru
Dolgikh T.Yu. – candidate of medical sciences, senior researcher, physician of hematology department with aseptic wards, e-mail: tatyana.yurevna.dolgikh@yandex.ru
D’yachkova Yu.A. – postgraduate student, physician of hematology department with aseptic wards, e-mail: dyachkova_yuliya@mail.ru
Maltseva N.A. – researcher, laboratory doctor, e-mail: pathol@soramn.ru
Kachesov I.V. – head of department of pathological anatomy, e-mail: pathol@soramn.ru
Marchenko A.A. – physician of department of pathological anatomy, e-mail: pathol@soramn.ru
